These clinical findings align with our prior theoretical and experimental results, reinforcing the critical role of SLC14A1, in tandem with the activation of the TGF-β pathway and EMT process, in promoting metachronous liver metastasis in CRC patients. This evidence concerns the gene SLC14A1 and colorectal carcinoma.